Clinical Study

British Journal of Cancer (2006) 95, 1142–1144. doi:10.1038/sj.bjc.6603422 www.bjcancer.com
Published online 10 October 2006

Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

N Takigawa1, K Kiura1, Y Segawa2, Y Watanabe3, H Kamei4, T Moritaka5, T Shibayama6, H Ueoka7, K Gemba8, T Yonei9, M Tabata1, T Shinkai2, S Hiraki3, M Takemoto10, S Kanazawa10, K Matsuo11 and M Tanimoto1 for the Okayama Lung Cancer Study Group

  1. 1Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences & Okayama University Hospital, Okayama 700-8558, Japan
  2. 2Department of Medicine and Thoracic Oncology, National Hospital Organization, Shikoku Cancer Center, Matsuyama 791-0288, Japan
  3. 3Department of Internal Medicine, Okayama Red Cross Hospital, Okayama 700-8607, Japan
  4. 4Department of Internal Medicine, Sumitomo Besshi General Hospital, Niihama 792-8543, Japan
  5. 5Department of Pulmonary Medicine, Ehime Prefectural Central Hospital, Matsuyama 790-0024, Japan
  6. 6Department of Pulmonary Medicine, National Hospital Organization, Minami-Okayama Medical Center, Tsukubo 701-0304, Japan
  7. 7Department of Medicine, National Hospital Organization, Sanyo Hospital, Ube 755-0241, Japan
  8. 8Department of Pulmonary Medicine, Okayama Rosai Hospital, Okayama 702-8055, Japan
  9. 9Department of Pulmonary Medicine, Okayama Medical Center, Okayama 701-1192, Japan
  10. 10Department of Radiology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences & Okayama University Hospital, Okayama 700-8558, Japan
  11. 11Department of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya 494-8681 Japan

Correspondence: Dr N Takigawa, E-mail: ntakigaw@md.okayama-u.ac.jp

Received 24 July 2006; Revised 18 September 2006; Accepted 22 September 2006; Published online 10 October 2006.

Top

Abstract

Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0–4.9).

Keywords:

non-small-cell lung cancer, chemotherapy, radiotherapy, second primary cancer